Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18207
Country/Region: Kenya
Year: 2017
Main Partner: Columbia University
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $3,242,218 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $202,545
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $146,568
Testing: HIV Testing and Counseling (HVCT) $132,216
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $101,393
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $59,733
Treatment: Adult Treatment (HTXS) $2,180,336
Treatment: Pediatric Treatment (PDTX) $419,427
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2018 492
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2018 184
GEND_GBV <10, Male, Physical and/or Emotional Violence 2018 24
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2018 9
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 397
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 148
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 56
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 21
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 484
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 181
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 24
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2018 9
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 326
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 122
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 64
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 24
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 268
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 101
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 16
GEND_GBV 25-49, Male, Sexual Violence (Post-Rape Care) 2018 6
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 322
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 2,152
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 804
GEND_GBV Number of people receiving post-GBV care 2018 2,956
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 43,914
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2018 5
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2018 287
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2018 988
HTS_TST Service Delivery Point (Facility) ANC: 25-49, Negative 2018 1,029
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2018 12
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2018 5
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2018 9
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 16
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 7
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 44
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 17
HTS_TST Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 79
HTS_TST Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 78
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2018 13
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2018 12
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2018 415
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2018 188
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2018 304
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2018 570
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2018 254
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2018 1,556
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2018 596
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative 2018 2,785
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative 2018 2,740
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2018 472
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2018 410
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 297
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 710
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 909
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 1,293
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 576
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 3,530
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 1,866
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 6,328
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 6,235
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 687
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 545
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2018 7
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2018 3
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2018 5
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 9
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2018 4
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 26
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 10
HTS_TST Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 46
HTS_TST Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 45
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2018 8
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2018 7
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 143
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 65
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 105
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 197
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 88
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 537
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 205
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 961
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 945
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2018 163
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2018 141
HTS_TST Service Delivery Point (Facility) VMMC: <1, Negative 2018 495
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2018 991
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2018 248
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2018 248
HTS_TST Service Delivery Point (Facility) VMMC: 25-49, Negative 2018 496
HTS_TST Sum of Test Result disaggregates 2018 1,842
HTS_TST_POS By Test Result: Positive 2018 1,842
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2018 38
HTS_TST_POS Service Delivery Point (Facility) ANC: 25-49, Positive 2018 108
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2018 31
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2018 14
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2018 22
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2018 60
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2018 22
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive 2018 192
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive 2018 145
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2018 19
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2018 21
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 38
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2018 25
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2018 33
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 40
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 15
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 105
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 39
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 340
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 233
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 33
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 37
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2018 21
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 66
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 50
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) VMMC: <1, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) VMMC: 10-14, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) VMMC: 15-19, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) VMMC: 20-24, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) VMMC: 25-49, Positive 2018 4
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2018 423
KP_MAT Sex: Female 2018 85
KP_MAT Sex: Male 2018 338
KP_MAT Sum of Sex disaggregates 2018 423
PMTCT_ART Already on ART at beginning of current pregnancy 2018 266
PMTCT_ART New on ART 2018 145
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 411
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 2,462
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 411
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 40
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 358
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 6
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 7
PMTCT_STAT By Age (Numerator): 15-19 2018 70
PMTCT_STAT By Age (Numerator): 20-24 2018 531
PMTCT_STAT By Age (Numerator): 25-49 2018 1,861
PMTCT_STAT By Number of known positives: 15-19 2018 5
PMTCT_STAT By Number of known positives: 20-24 2018 59
PMTCT_STAT By Number of known positives: 25-49 2018 215
PMTCT_STAT By Number of new negative: 15-19 2018 39
PMTCT_STAT By Number of new negative: 20-24 2018 429
PMTCT_STAT By Number of new negative: 25-49 2018 1,562
PMTCT_STAT By Number of new positives: 15-19 2018 25
PMTCT_STAT By Number of new positives: 20-24 2018 42
PMTCT_STAT By Number of new positives: 25-49 2018 86
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 2,462
PMTCT_STAT_den By Age (Denominator): <15-19 2018 70
PMTCT_STAT_den By Age (Denominator): 20-24 2018 531
PMTCT_STAT_den By Age (Denominator): 25-49 2018 1,861
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 4
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 46
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 2
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 24
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 76
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 76
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 4
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 46
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 2
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 24
TB_PREV By Age/Sex (Numerator): <15, Female 2018 47
TB_PREV By Age/Sex (Numerator): <15, Male 2018 24
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 1,113
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 574
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 1,758
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 1,758
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 1,953
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 53
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 26
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 1,237
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 637
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 1,953
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 7
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 86
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 3
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 45
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 141
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 144
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 7
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 88
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 3
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 46
TX_CURR Age/Sex: <1 2018 11
TX_CURR Age/Sex: <1-9 2018 331
TX_CURR Age/Sex: 10-14 Female 2018 103
TX_CURR Age/Sex: 10-14 Male 2018 116
TX_CURR Age/Sex: 15-19 Female 2018 153
TX_CURR Age/Sex: 15-19 Male 2018 113
TX_CURR Age/Sex: 20-24 Female 2018 310
TX_CURR Age/Sex: 20-24 Male 2018 71
TX_CURR Age/Sex: 25-49 Female 2018 3,900
TX_CURR Age/Sex: 25-49 Male 2018 1,725
TX_CURR Age/Sex: 50+ Female 2018 732
TX_CURR Age/Sex: 50+ Male 2018 736
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 8,301
TX_CURR Sum of age/sex disaggregates 2018 266
TX_NEW Breastfeeding status 2018 13
TX_NEW By Age/Sex: <1 2018 1
TX_NEW By Age/Sex: 1-9 2018 31
TX_NEW By Age/Sex: 10-14 Female 2018 31
TX_NEW By Age/Sex: 10-14 Male 2018 16
TX_NEW By Age/Sex: 15-19 Female 2018 124
TX_NEW By Age/Sex: 15-19 Male 2018 64
TX_NEW By Age/Sex: 20-24 Female 2018 247
TX_NEW By Age/Sex: 20-24 Male 2018 127
TX_NEW By Age/Sex: 25-49 Female 2018 371
TX_NEW By Age/Sex: 25-49 Male 2018 191
TX_NEW By Age/Sex: 50+ Female 2018 495
TX_NEW By Age/Sex: 50+ Male 2018 255
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 1,953
TX_NEW Pregnancy status 2018 118
TX_NEW Sum of Age/Sex disaggregates 2018 1,921
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 8,290
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 7,406
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 224
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 31
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 186
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 4,386
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 259
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 2,091
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 229
TX_PVLS Numerator: Indication: Routine 2018 6,887
TX_PVLS Numerator: Indication: Targeted 2018 519
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Routine 2018 28
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Targeted 2018 2
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 21
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Targeted 2018 2
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 280
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 39
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 233
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 4,874
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 287
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 2,323
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 254
TX_PVLS_den Denominator: Indication: Routine 2018 7,710
TX_PVLS_den Denominator: Indication: Targeted 2018 580
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Routine 2018 31
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Targeted 2018 2
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 23
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Targeted 2018 2
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 50
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 26
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,174
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 605
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 1,855
TX_RET Numerator by Status: Breastfeeding 2018 4
TX_RET Numerator by Status: Pregnant 2018 6
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 3,024
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 346
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 178
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 2,500
TX_RET_den Denominator by Status: Breastfeeding 2018 6
TX_RET_den Denominator by Status: Pregnant 2018 9
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 8,301
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 31
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 1
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 1
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 19
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 10
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 78
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 39
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 1,018
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 525
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 249
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 83
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 1,328
TX_TB_den Denominator: By Screen Result: Negative 2018 6,641
TX_TB_den Denominator: By Screen Result: Positive 2018 1,660
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 1,660
VMMC_CIRC By Age: 0-60 days 2018 500
VMMC_CIRC By Age: 10-14 2018 1,000
VMMC_CIRC By Age: 15-19 2018 250
VMMC_CIRC By Age: 20-24 2018 250
VMMC_CIRC By Age: 25-29 2018 500
VMMC_CIRC By circumcision technique: Device-based VMMC 2018 154
VMMC_CIRC By circumcision technique: Surgical VMMC 2018 2,346
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2018 2,500
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2018 2,000
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2018 1,500
Cross Cutting Budget Categories and Known Amounts Total: $1,731,484
Gender: Gender Equality $2,873
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Gender: Gender Based Violence (GBV) $2,873
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Education $95,705
Human Resources for Health $1,630,033